| Literature DB >> 26446553 |
Abstract
INTRODUCTION: Low carbohydrate diets are again in the spotlight and have been identified as particularly appropriate for people with type 2 diabetes. There is confusion amongst both health professionals and people with diabetes about the suitability of these diets. This review aims to provide an overview of the latest evidence and to explore the role of low carbohydrate diets for people with type 2 diabetes.Entities:
Keywords: Cardiovascular risk; Glycemic control; Low carbohydrate diet; Type 2 diabetes; Weight loss
Year: 2015 PMID: 26446553 PMCID: PMC4674467 DOI: 10.1007/s13300-015-0136-9
Source DB: PubMed Journal: Diabetes Ther Impact factor: 2.945
Taxonomy of diets containing differing amounts of carbohydrate
| Description | Amount of carbohydrate | |
|---|---|---|
| g/day | % total energy intake | |
| Very low carbohydrate ketogenic diet | 20–50 | ≤10 |
| Low carbohydrate | <130 | <26 |
| Moderate carbohydrate | 130–230 | 26–45 |
| High carbohydrate | >230 | >45 |
Adapted from Feinman et al. [4]
Fig. 1Study flow diagram showing number of studies screened, assessed for eligibility, and included in the narrative review
Descriptive summary of recent low carbohydrate trials for people with type 2 diabetes
| First author, year | Duration (months) | Numbers | Diet | ||
|---|---|---|---|---|---|
| I | C | I | C | ||
| Iqbal, 2010 [ | 24 | 70 | 74 | ≤30 g/day carbohydrate | ≤30% fat, 500 kcal/day energy deficit |
| Elhayany, 2010 [ | 12 | 85 | 174 | 35% carbohydrate, 45% fat (50 % of which was MUFA) | 1. ADA diet: 50–55% carbohydrate, 15–10% protein, 30% total fat 2. Mediterranean diet: as ADA diet, but MUFA fat |
| Larsen, 2011 [ | 12 | 53 | 46 | 40% carbohydrate, 30% protein, 30% fat | 55% carbohydrate, 15% protein, 30% fat |
| Guldbrand, 2012 [ | 24 | 30 | 31 | 20% carbohydrate, 30% protein, 50% fat | 55–60% carbohydrate, 10–25% protein, 30% fat |
| Krebs, 2013 [ | 24 | 207 | 211 | 40% carbohydrate, 30% protein, 30% fat | 55% carbohydrate, 15% protein, 30% fat |
| Mayer, 2014 [ | 11.5 | 22 | 24 | ≤20 g/day carbohydrate | ≤30% fat, 500–1000 kcal/day energy deficit and orlistat |
| Yamada, 2014 [ | 6 | 12 | 12 | 70–130 g/day carbohydrate to avoid ketosis | 50–60% carbohydrate, <20% protein, <25% fat, with energy restriction based on Japanese recommendations |
| Tay, 2015 [ | 6 | 46 | 47 | <50 g/day carbohydrate (14%) | 53% low GI carbohydrate, 17% protein, 30% fat |
ADA American Diabetes Association, C comparator, GI glycemic index, I intervention, MUFA monounsaturated fatty acids
Summary of results of recent low carbohydrate trials for people with type 2 diabetes (body weight and glycemic control)
| First author, year | Body weight loss (kg) | Changes in HbA1c (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| I | C | I − C |
| I | C | I − C |
| |
| Iqbal, 2010 [ | 1.7 | 0.2 | 1.2 | 0.29 | −0.1 | −0.2 | −0.1 | NS |
| Elhayany, 2010 [ | 8.9 | 7.6 | 1.4 | 0.557 | −2.0 | −1.6 | −0.4 | 0.88 |
| Larsen, 2011 [ | 2.23 | 2.17 | 0.07 | 0.9 | −0.23 | −0.28 | 0.04 | 0.76 |
| Guldbrand, 2012 [ | 2.0 | 2.9 | −0.9 | 0.33 | 0.0 | 0.2 | −0.2 | 0.76 |
| Krebs, 2013 [ | 3.9 | 6.0 | −2.1 | 0.73 | 0.1 | 0.1 | 0.0 | 0.5 |
| Mayer, 2014 [ | 7.5 | 8.1 | −0.6 | 0.8 | −0.7 | 0.2 | −0.8 | 0.045 |
| Yamada, 2014 [ | 2.6 | 1.4 | 1.2 | 0.8 | −0.6 | 0.2 | −0.4 | 0.03 |
| Tay, 2014 [ | 12.0 | 11.5 | 0.5 | 0.57 | NR | NR | NR | NR |
C comparator, HbA1c glycated hemoglobin, I intervention, NR not reported, NS no significant difference
Summary of results of recent low carbohydrate trials for people with type 2 diabetes (cardiovascular risk)
| First author, year | Total cholesterol (mmol/L) | HDL (mmol/L) | LDL (mmol/L) | Triglycerides (mmol/L) | Systolic BP (mm/Hg) | Diastolic BP (mm/Hg) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I − C |
| I − C |
| I − C |
| I − C |
| I − C |
| I − C |
| |
| Iqbal, 2010 [ | 0.03 | NS | 0.0 | NS | −0.06 | NS | −0.14 | NS | −6.7 | NS | 0.5 | NS |
| Elhayany, 2010 [ | −0.02 | 0.204 | 0.18 | <0.001 | −0.24 | 0.036 | −0.64 | <0.001 | NR | NR | NR | NR |
| Larsen, 2011 [ | −0.16 | 0.32 | 0.01 | 0.84 | −0.01 | 0.3 | −0.17 | 0.34 | −4.3 | 0.05 | −0.4 | 0.7 |
| Guldbrand, 2012 [ | 0.2 | 0.33 | 0.12 | 0.15 | 0.0 | 0.16 | 0.1 | 0.35 | 2 | 0.74 | 3 | 0.75 |
| Krebs, 2013 [ | −0.07 | 0.03 | 0.01 | 0.41 | 0.03 | 0.32 | −0.03 | 0.02 | 1 | 0.87 | 0.0 | 0.96 |
| Mayer, 2014 [ | 0.23 | 0.4 | 0.03 | 0.5 | 0.25 | 0.3 | −0.28 | 0.3 | −11 | 0.006 | −6 | 0.013 |
| Yamada, 2014 [ | NR | NR | 0.25 | 0.13 | −0.08 | 0.49 | −0.58 | 0.08 | 1.7 | 0.54 | −4.6 | 0.3 |
| Tay, 2014 [ | 0.0 | 0.89 | NR | NR | 0.0 | 0.81 | −0.4 | 0.001 | −2.3 | 0.26 | −1.8 | 0.1 |
BP blood pressure, C comparator, HDL high density lipoprotein, I intervention, LDL low density lipoprotein, NR not reported, NS no significant difference